

## **PUBLIKATIONEN - Originalarbeiten**

Schöniger-Hekele M, Petermann D, Lesch OM, Müller Ch. Prevalence of hepatitis G-virus infection in alcohol abusing patients with and without liver cirrhosis.

Wien Klin Wochenschr 1998; 110/19: 686-690.

Tribl B., Schöniger-Hekele M., Petermann D., Bakos S., Penner E., Müller Ch. Prevalence of GBV-C/HGV-RNA, virus genotypes and anti-E2 antibodies in autoimmune hepatitis.

Am J Gastroenterol 1999; 94:3336-3340

Schöniger-Hekele M, Müller Ch, Kutilek M, Oesterreicher Ch, Ferenci P, Gangl A. Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation.

Eur J Gastroenterol Hepatol 2000; 12:941-948

Schöniger-Hekele M, Müller Ch, Kutilek M, Oesterreicher Ch, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: Prognostic features and survival.

Gut 2001; 48:103-109

Schöniger-Hekele M, Müller Ch. Elevated serum levels of sFas in acute viral hepatitis.

Correspondence: Eur J Gastroenterol Hepatol 2001; 13:1507-1508

Schöniger-Hekele M, Müller Ch, Polli C, Wrba F, Penner E, Ferenci P. Liver pathology in compound heterozygous patients for hemochromatosis mutations.

Liver 2002; 22(4):295-301.

Schöniger-Hekele M, Müller Ch, Ackermann J, Drach J, Wrba F, Penner E, Ferenci P. Lack of evidence for involvement of fetal microchimerism in the pathogenesis of primary biliary cirrhosis.

Dig Dis Sci 2002; 47(9):1909-1914

Reinisch W, Holub M, Katz A, Herneth A, Lichtenberger C, Schöniger-Hekele M, Waldhoer T, Oberhuber G, Ferenci P, Gangl A, Mueller C. Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma.

J Immunother. 2002 Nov-Dec;25(6):489-99

Cauza E, Peck-Radosavljevic M, Ulrich-Pur H, Datz C, Gschwantler M, Schöniger-Hekele M, Hackl F, Polli C, Rasoul-Rockenschaub S, Muller C, Wrba F, Gangl A, Ferenci P. Mutations of the HFE gene in patients with hepatocellular carcinoma.

Am J Gastroenterol. 2003 Feb;98(2):442-7.

Schenk P, Schöniger-Hekele M, Fuhrmann V, Madl C, Silberhumer G, Muller C. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis.

Gastroenterology. 2003 Oct;125(4):1042-52.

Schöniger-Hekele M, Hänel S, Wrba F, Müller C. Hepatocellular carcinoma – survival and clinical characteristics in relation to various histologic molecular markers in Western patients. Liver Int. 2005 Feb; 25(1):62-9.

Schöniger-Hekele M, Müller C. The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis.

Dig Dis Sci. 2006 Feb;51(2):338-45.

Schöniger-Hekele M, Ramskogler K, Hartl D, Lesch OM, Müller C. Exclusion of trisialo-transferrin from carbohydrate-deficient transferrin measurement: advantage in patients with chronic liver disease?

Wien Med Wochenschr. 2006;156(7-8):216-22

Schöniger-Hekele M, Petermann D, Müller C. Mutation of keratin 8 in patients with liver disease. J Gastroenterol Hepatol. 2006 Sep;21(9):1466-9.

Schöniger-Hekele M, Petermann D, Weber B, Müller C. Tropheryma whipplei in the Environment: Survey of Sewage Plant Influxes and Sewage Plant Workers. Appl Environ Microbiol. 2007;73(6): 2033–2035

Schöniger-Hekele M, Müller C, Kramer L, Dauber E, Mayr WR, Wrba F, Rockenschaub S, Muhlbacher F. Graft versus Host Disease after Orthotopic Liver Transplantation Documented by Analysis of Short Tandem Repeat Polymorphisms. Digestion. 2007;74(3-4):169-173

Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, Schöniger-Hekele M, Holzmann H, Steindl-Munda P. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology. 2008;135(5):1561-7. Epub 2008 Aug 3.

Müller C, Schöniger-Hekele M, Schernthaner R, Renner B, Peck-Radosavljevic M, Brichta A, Wrba F, Posch M, Bauer P, Ferenci P, Gangl A. Percutaneous ethanol instillation therapy for hepatocellular carcinoma - a randomized controlled trial. Wien Klin Wochenschr. 2008;120(19-20):608-618.

Schöniger-Hekele M, Kettenbach J, Peck-Radosavljevic M, Müller C. Octreotide treatment of patients with hepatocellular carcinoma--a retrospective single centre controlled study. J Exp Clin Cancer Res. 2009 Nov 3;28:142.

Sahinbegovic E, Dallos T, Aigner E, Axmann R, Engelbrecht M, Schöniger-Hekele M, Karonitsch T, Farkas M, Karger T, Willeit J, Stölzel U, Keysser G, Datz C, Kiechl S, Schett G, Zwerina J. Hereditary hemochromatosis as a risk factor for joint replacement surgery. Am J Med. 2010 Jul;123(7):659-62.

Schöniger-Hekele M, Müller C. Pilot study: rapamycin in advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2010 Sep;32(6):763-8. doi: 10.1111/j.1365-2036.2010.04404.x

Dallos T, Sahinbegovic E, Aigner E, Axmann R, Schöniger-Hekele M, Karonitsch T, Stamm T, Farkas M, Karger T, Cavallaro A, Stölzel U, Keysser G, Datz C, Schett G, Manger B, Zwerina J. Validation of a radiographic scoring system for haemochromatosis arthropathy. Ann Rheum Dis. 2010 Dec;69(12):2145-51. Epub 2010 Aug 2.

Ferlitsch A, Schoefl R, Puespoek A, Miehsler W, Schoeniger-Hekele M, Hofer H, Gangl A, Homoncik M. Effect of virtual endoscopy simulator training on performance of upper gastrointestinal endoscopy in patients: a randomized controlled trial. *Endoscopy*. 2010 Dec;42(12):1049-56. Epub 2010 Oct 22.

Sahinbegovic E, Dallos T, Aigner E, Axmann R, Manger B, Englbrecht M, Schöniger-Hekele M, Karonitsch T, Stamm T, Farkas M, Karger T, Stölzel U, Keysser G, Datz C, Schett G, Zwerina J. Musculoskeletal disease burden of hereditary hemochromatosis. *Arthritis Rheum*. 2010 Dec;62(12):3792-8. doi: 10.1002/art.27712.

Fuhrmann V, Kneidinger N, Herkner H, Heinz G, Nikfardjam M, Bojic A, Schellongowski P, Angermayr B, Schöniger-Hekele M, Madl C, Schenk P. Impact of hypoxic hepatitis on mortality in the intensive care unit. *Intensive Care Med*. 2011 Aug;37(8):1302-10. Epub 2011 Jun 7.

Hucke F, Sieghart W, Schöniger-Hekele M, Peck-Radosavljevic M, Müller C. Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program? *Wien Klin Wochenschr*. 2011 Sep;123(17-18):542-51. Epub 2011 Jul 29.

Pinter M, Sieghart W, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Matejka J, Stauber R, Buder R, Grünberger B, Schöniger-Hekele M, Müller C, Peck-Radosavljevic M. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. *Aliment Pharmacol Ther*. 2011 Oct;34(8):949-59. doi: 10.1111/j.1365-2036.2011.04823.x. Epub 2011 Aug 24.

Peck-Radosavljevic M, Sieghart W, Kölblinger C, Reiter M, Schindl M, Ulbrich G, Steininger R, Müller C, Stauber R, Schöniger-Hekele M, Gschwendtner M, Plank C, Funovics M, Graziadei I, Lammer J, Gruenberger T, Gastl G, Karnel F; the Austrian Association of Gastroenterology, Hepatology (ÖGGH); the Austrian Society of Interventional Radiology (ÖGIR); the Austrian Society of Hematology and Oncology (ÖGHO); the Austrian Society for Surgical Oncology (ASSO). Austrian Joint ÖGGH-ÖGIR-ÖGHO-ASSO position statement on the use of transarterial

chemoembolization (TACE) in hepatocellular carcinoma. Wien Klin Wochenschr. 2012 Feb;124(3-4):104-10. doi: 10.1007/s00508-011-0056-2. Epub 2011 Sep 22

Sieghart W, Pinter M, Hucke F, Graziadei I, Schöniger-Hekele M, Müller C, Vogel W, Trauner M, Peck-Radosavljevic M. A single determination of C-reactive protein at the time of diagnosis predicts long term outcome of patients with hepatocellular carcinoma. Hepatology. 2012 Sep 7. doi: 10.1002/hep.26057.